Sep 15, 2023
Mimicry Solutions would like to welcome Katie Sokolowski, PhD, DABT to our Advisory Board! Dr. Sokolowski is a former FDA pharm/tox reviewer within CDER and we are excited to leverage her expertise in the development of ARTEMIS™.
About Dr. Sokolowski
Dr. Sokolowski previously spent six years at the FDA as a pharm/tox reviewer for CDER. At the FDA, she was responsible for nonclinical review of INDs and NDA/BLAs while actively participating in the Neurotoxicity Assessment Subcommittee and the Extractable and Leachable Subcommittee, spearheading the intramural DABT study group, and developing lectures for the Education Subcommittee of the Pharmacology/Toxicology Coordinating Committee. Currently, she is a Principal Toxicologist at Denali Therapeutics where she is responsible for nonclinical safety assessment strategies and regulatory interactions for large and small molecules in the neurodegenerative disease therapeutic area. She is an active member of the Society of Toxicology (SOT), the American College of Toxicology (ACT), and the Society of Toxicologic Pathology (STP). She completed a postdoctoral fellowship at the Center for Neuroscience at Children’s National Medical System, Washington, DC, holds a PhD in toxicology from the Joint Graduate Program in Toxicology (JGPT), Rutgers University/UMDNJ, and is a Diplomate of the American Board of Toxicology.
About Mimicry Solutions
Mimicry Solutions is disrupting the pharmaceutical industry with ARTEMIS™, a proprietary toxicology platform that is the first ever alternative to animal testing for drug safety assessments at the industry level. ARTEMIS™ will generate novel toxicological readouts that outperform animals, providing better safety assessments of new drugs, faster drug development timelines, and a reduced ethical burden in animal research. Learn more at www.mimicrysolutions.com.